Snyderman/Mikovits Poster Presentation

This presentation, of great historical importance, from the 1st International Workshop on XMRV, is posted with permission:

XMRV:  Virological, immunological and clinical correlations in patients with Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
M. Snyderman, I. Sylvester-Brao, D. Goetz, K. Hagen, V.C. Lombardi, D.L. Peterson, P.H. Levine, F.W. Ruscetti, J.A. Mikovits

Link to Powerpoint Presentation
Link to presentation as a pdf

Did you like this? Share it:

12 thoughts on “Snyderman/Mikovits Poster Presentation

  1. >Wow, How encouraging to see such a big improvement in this patient's cytokine profile in such a short period of time. And the DERSE assay CAN measure viral load! Even though this is an n of 1, it shows evidence that ARVs work and that clinical trials should be happening NOW. Thanks to the authors for giving Dr. Deckoff-Jones permission to share this important piece of the XMRV Workshop with us.

  2. >Dr.Deckoff-Jones,

    It would be helpful for us, who do not have such in dept knowledge of science, if you could summarize this presentation in simplified version.

    Thank you

  3. >There is a "random forest" graph of the most important cytokines in predicting whether a person is XMRV positive, but some are too small to read. Do you know what they are?

  4. >Thank you for sharing , Dr Jamie, I also appreciated that you asked permission first.

    May the scientists pay attention and start studying aobut Me/CFS with those experts that know already.


  5. >At the top, center right of the powerpoint slide toolbar is a magnifying glass icon, which will allow you to zoom in and read the data, bit by bit.

    Thanks again JDJ. Important stuff.

  6. >There are many historically important things about this study, but the ones that are pretty mind-blowing in my view:
    1. That XMRV could be both detected in these cancerous cells and generated (expressed) from cell cultures made from these cells makes for a strong association between the virus and the diseases.
    2. That antiretroviral therapy lowers not only cytokine markers for XMRV, as one might expect, but actually lowers markers for the tumors themselves… along with clinical improvements, strengthens the potential causal association.

    3. #2 is just mind-boggling because it suggests that the cancerous conditions are being driven or maintained by the continuous presence of the virus, rather than that the virus turns on the genes for the cancer (or off genes that prevent it) and then its presence or absence has no effect.

    Think of it this way- you could treat these cancers by antiretrovirals rather than chemo, radiation or surgery.

    Or another way- maybe cancer is the result not the problem.

    This is big stuff if it bears out in larger groups.

    Besides all that, there is that little thing of those folks who are XMRV positive being able to prevent potential cancer…

  7. >Jamie – Thanks for posting your progress and perspective. So nice to hear the combined patient/doctor viewpoint from one person. Question: When deciding to go on antiretrovirals, did you look at any other alternatives. I am hearing about a peptide treatment that, while expensive, is having good results. Also, some researchers at the XMRV conference mentioned an anti-TSG101 peptide that they were very optimistic about. Lastly, have you heard of any correlation of XRMV and melanoma? Thanks.

  8. >Thanks a lot, Dr. Deckoff-Jones!
    I want to let you know that there is a little mistake in the PowerPoint file. In figure 4 in the PowerPoint file it says that the year of those tests is 2006, while you can clearley see in the PDF file that the year is 2010. I think it would be best if you would upload a corrected version, and anyway, remove the current PowerPoint version because it's mistakingly misleading.

    About the poster itself, I have to say that I don't understand much, because I'm not a scientist, but this is really intruiging and I hope they'll perform larger studies regarding that subject.

Comments are closed.